TGFβ targeting CAR-T cells
/ Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 25, 2024
ZZCART-003: GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2029 ➔ Aug 2036 | Trial primary completion date: Aug 2025 ➔ Aug 2029
CAR T-Cell Therapy • IO biomarker • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • GPC3
February 28, 2023
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2024 ➔ Aug 2029 | Trial primary completion date: Aug 2022 ➔ Aug 2025
CAR T-Cell Therapy • IO biomarker • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • GPC3
December 01, 2020
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Second Affiliated Hospital of Guangzhou Medical University; Trial completion date: Aug 2022 ➔ Aug 2024; Trial primary completion date: Aug 2020 ➔ Aug 2022
Clinical • IO Biomarker • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1